MEASUREMENT OF O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE IN HUMAN TUMORS

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$500,000.00
Award Year:
1992
Program:
SBIR
Phase:
Phase II
Contract:
n/a
Agency Tracking Number:
13737
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Applied Genetics Inc.
205 Buffalo Ave, Freeport, NY, 11520
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Daniel B Yarosh
(516) 868-9026
Business Contact:
() -
Research Institution:
n/a
Abstract
NITROSOUREAS ARE EFFECTIVE ANTITUMOR AGENTS, ESPECIALLY IN BRAIN CANCER. HOWEVER, TUMORS ARE OFTEN RESISTANT DUE TO ACTIVITY OF THE HUMAN DNA REPAIR ENZYME, O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE (O6MT). THE OUTCOME OF CHEMOTHERAPY MAY BE PREDICTED BY MEASURING THE LEVELS OF O6MT IN SINGLE CELLS FROM TUMOR BIOPSIES, AND A MORE RATIONAL TREATMENT REGIME MAY BE DESIGNED. THIS APPROACH IS NOW FEASIBLE BECAUSE OF THE CLONING OF THE HUMANO6MT GENE. THE PHASE I RESEARCH WILL USE POLYCLONAL ANTIBODIES AND DNA PROBES TO MEASURE O6MT LEVELS IN HUMAN TUMOR SAMPLES TAKEN AT INITIAL BIOPSY AND AT SECOND-LOOK SURGERY. THE IMMUNOHISTOCHEMICAL AND IN SITU HYBRIDIZATION ASSAY WILL BE DEVELOPED, AND TEST RESULTS WILL BE CORRELATED WITH PATIENT OUTCOME. THIS WILL ESTABLISH THE USEFULNESS OF THESE ASSAYS IN A CLINICAL TRIAL TO PREDICT DRUG RESISTANCE AND PATIENT RESPONSE TO TREATMENT.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government